Tusk Innovation ประกาศเปิดตัวผลิตภัณฑ์ใหม่ “แบบผสานรวม”

TUSK PRODUCT

TUSK PRODUCT ZEN

ลอนดอน, Nov. 25, 2022 (GLOBE NEWSWIRE) — Tusk Inc. Limited (www.tusklimited.com) บริษัทซึ่งเริ่มก่อตั้งขึ้นในปี 2012 เพื่อเป็นบริษัทจัดการเงินทุนในสหราชอาณาจักรและกัวลาลัมเปอร์ โดยมีสำนักงานอยู่ทั่วโลกและปัจจุบันเป็นหนึ่งในบริษัทชั้นนำด้านโซลูชันไฟฟ้าที่มุ่งเน้นการผลิตไฟฟ้าสำหรับผู้ใช้อุปกรณ์การขุดสกุลเงินดิจิทัล พลังงานแสงอาทิตย์ และอะแดปเตอร์นั้น ได้ประกาศเปิดตัวผลิตภัณฑ์ใหม่ที่เป็นการผสานรวมการทำงาน สายผลิตภัณฑ์นี้ส่วนใหญ่มีไว้ใช้เพื่อวัตถุประสงค์ทางไฟฟ้า สำหรับนักขุดบิตคอยน์ ผลิตภัณฑ์ดังกล่าวมาพร้อมกับแผงโซลาร์เซลล์เพื่อลดการใช้พลังงาน ดูผลิตภัณฑ์ที่นี่ https://tusklimited.com/products

ในฐานะที่เป็นหนึ่งในสุดยอดบริษัทโซลูชันไฟฟ้า Tusk Innovation ได้ประกาศส่วนลด 30% สำหรับชุดอุปกรณ์การขุดเหรียญที่ผสานรวมแผงโซลาร์เซลล์เข้ากับเครื่องขุดบิตคอยน์ เมื่อเร็วๆ นี้ Tusk Inc. ได้เปลี่ยนจากวัสดุโพลีคริสตัลไลน์ (Polycrystalline) ไปเป็นโฟโตวอลเทอิก (Photovoltaic) และได้ทดสอบประสิทธิภาพของการผสมผสานผลิตภัณฑ์พลังงานแสงอาทิตย์เข้ากับเครื่องขุดสกุลเงินดิจิทัล และได้พิสูจน์แล้วว่าการผสมผสานนี้ทำให้เกิดประสิทธิผลมากที่สุด ขณะนี้นักลงทุน Tusk Inc. สามารถขุดเหรียญของตนได้อย่างง่ายดายโดยไม่มีการหยุดชะงัก จึงมีความเสี่ยงน้อยกว่าและทำกำไรได้สูงสุด

นี่คือความพยายามที่จะลดปริมาณการใช้ไฟฟ้าขณะที่ลูกค้าขุดสกุลเงินดิจิทัล และ John Walls ประธานเจ้าหน้าที่บริหาร ได้เปิดเผยเรื่องนี้เมื่อสัปดาห์ที่แล้ว จากคำกล่าวของ Walls ที่ว่า “รายงานต่าง ๆ ที่เผยแพร่ไปทั่วนั้นทำให้เห็นได้ชัดว่า ปริมาณไฟฟ้าที่นักขุดเหรียญต้องใช้นั้นอาจมากเกินที่จะจัดการได้ ดังนั้นเราจึงจัดให้มีตัวเลือกที่สมเหตุสมผล”

กำไรจากการขุดเหรียญ
แม้ว่าการทำฟาร์มขุดสกุลเงินดิจิทัลจะเป็นสิ่งที่น่าชื่นชมและทำกำไรได้สูงสำหรับหลายคน แต่ก็เป็นที่ทราบกันแพร่หลายในเรื่องการเก็งกำไรว่า นักขุดเหล่านั้นอาจมีค่าใช้จ่ายจำนวนมาก โดยเฉพาะอย่างยิ่งในแง่ของการใช้ไฟฟ้า การให้บริการแผงโซลาร์เซลล์ ซึ่งไม่มีส่วนเชื่อมโยงกับค่าไฟฟ้าของคุณและอุปกรณ์การขุดบิตคอยน์ที่สามารถทำงานโดยขุดสองเหรียญพร้อมกันได้นั้น ทำให้ Tusk Inc. สร้างโซลูชันที่ใช้งานได้ยาวนาน คุณสามารถขุดเหรียญได้อย่างง่ายดายและไม่ต้องกังวลเกี่ยวกับความผันผวนของตลาด พร้อมกับไม่ต้องสนใจการใช้พลังงานอีกด้วย

Tusk Inc. ได้สร้างความแตกต่างจากผู้ให้บริการรายอื่น โดยทำให้ลูกค้าได้รับบริการพัฒนากระเป๋าเงินคริปโตและได้รับหน่วยประมวลผลกราฟิกจากบริษัท ซึ่งมีสำนักงานต่าง ๆ อยู่ในสามทวีป บริษัทแห่งนี้ยังมีประสบการณ์มากมายในด้านการพัฒนาบล็อกเชน (Blockchain) และโซลูชันการขุดบิตคอยน์นอกเหนือจากด้านอื่น ๆ อีกด้วย

เกี่ยวกับ Tusk
Tusk Inc. ก่อตั้งขึ้นในปี 2012 โดยทีมผู้เชี่ยวชาญด้านการจัดการ แล้วต่อมาก็ได้ทีมผู้เชี่ยวชาญด้านเทคโนโลยีมาร่วมงานด้วย และขณะนี้ก็ถือเป็นหนึ่งในผู้ให้บริการโซลูชันไฟฟ้าชั้นนำ ผู้นำรายนี้ยังภาคภูมิใจในความสามารถในการจัดการความเสี่ยงได้อย่างมีประสิทธิผล เนื่องจากอยู่ในธุรกิจด้านการจัดการความเสี่ยงมาเป็นเวลานานกว่าทศวรรษแล้ว และจากความก้าวหน้าหลายอย่างในเทคโนโลยี พวกเขาจึงได้รวมกิจการร่วมทุนที่มีความเสี่ยงน้อยกว่าเข้ากับระบบการจัดการความเสี่ยง ซึ่งหนึ่งในนั้นก็คือการขุดสกุลเงินดิจิทัลโดยใช้วัสดุโฟโตวอลเทอิก

John Walls
ผู้จัดการฝ่ายประชาสัมพันธ์
john@tusklimited.com
(+44)7451214344

รูปภาพประกอบของการแถลงนี้สามารถรับชมได้ที่ https://www.globenewswire.com/NewsRoom/AttachmentNg/3b9f1b17-0a1a-4dce-bab8-8ffb601ccfac

GlobeNewswire Distribution ID 1000768791

KlasJet adds Boeing 737 BBJ2 to its exclusive fleet

KlasJet adds Boeing 737 BBJ2 to its exclusive fleet

The Boeing 737 BBJ2 is a splendid addition to KlasJet’s exclusive private aircraft fleet as it is set to cater to the specific needs of high-ranking clients travelling in smaller groups.

LONDON, Nov. 24, 2022 (GLOBE NEWSWIRE) — In 2021, the global business jet market was USD 25.87bn and is expected to reach USD 38.34bn by 2029, growing at a CAGR of 4.06 %. Business jets flew 3.3 million flights worldwide in 2021, the most on record for a single year and 7 % more than the previous high point in 2019. Private jet statistics show a global fleet of 21,929 registered aircraft.

KlasJet adds Boeing 737 BBJ2 to its exclusive fleet

The Boeing 737 BBJ2 is a splendid addition to KlasJet’s exclusive private aircraft fleet as it is set to cater to the specific needs of high-ranking clients travelling in smaller groups.

To expand KlasJet’s products portfolio, an EU-based corporate charter and ACMI services provider is adding Boeing BBJ2, MSN 32971 jet to its fleet. The aircraft is set to begin operations in mid-April 2023 and will be based in Dubai. The general sales agent for this aircraft will be Chapman Freeborn UAE Dubai office.

KlasJet adds Boeing 737 BBJ2 to its exclusive fleet

The Boeing 737 BBJ2 is a splendid addition to KlasJet’s exclusive private aircraft fleet as it is set to cater to the specific needs of high-ranking clients travelling in smaller groups.

The Boeing 737 BBJ2 is a splendid addition to KlasJet’s exclusive private aircraft fleet as it is set to cater to the specific needs of high-ranking clients travelling in smaller groups. “While our other 56-68 seats VIP Boeing 737 uniquely designed jets are great for larger groups, such as sports teams, business and political delegations, the B737 BBJ2 will serve as an amazing choice for affluent families, government representatives, presidents, royal families, important business delegations. Currently, the aircraft is at Avia Solutions Group completion centre JetMS Completion, where the interior of the jet will be fully renewed,” explains Rita Domkute, CEO of KlasJet.

KlasJet adds Boeing 737 BBJ2 to its exclusive fleet

The Boeing 737 BBJ2 is a splendid addition to KlasJet’s exclusive private aircraft fleet as it is set to cater to the specific needs of high-ranking clients travelling in smaller groups.

 

Corporate business jet charter services are in great demand all over the world, as big groups can travel enjoying all the perks of business aviation: flexible flight time, luxury service on board, special seats and price per seat similar to business class seats at regular airline companies. “We plan that the newly added B737 BBJ2 will allow us to strengthen our positions in the rapidly growing Middle East market as the jet is a perfect option for high-ranking individuals who are living in or visiting the region on regular basis,” she shares.

The 23-seat aircraft is a truly exquisite project, with a spacious lounge area, an on-board bedroom and a shower. “The jet is designed to meet even the most sophisticated needs of our clients. It is planned with convenience and comfort of passengers in mind, the design is created using high-quality materials,” KlasJet’s CEO shares.

KlasJet adds Boeing 737 BBJ2 to its exclusive fleet

The Boeing 737 BBJ2 is a splendid addition to KlasJet’s exclusive private aircraft fleet as it is set to cater to the specific needs of high-ranking clients travelling in smaller groups.

Earlier this year, the airline added passenger ACMI services list, adding to its parent company Avia Solutions Group’s ever-growing line-up of capacity providers.

If you would like more information or would like to schedule an interview with one of our KlasJet representatives, please contact Vilma Vaitiekunaite at vilma.vaitiekunaite@aviasg.com or +37061112789

About KlasJet 
KlasJet is an exlusive private and corporate jet charter company, renowned as a leader in the provision of bespoke group flights worldwide. Operating a fleet of uniquely designed jets based in Vilnius, Lithuania, as well as airports across Western and Eastern Europe, Africa, and the Middle East, KlasJet provides comfort, safety, and attention to detail from the ground up.

KlasJet adds Boeing 737 BBJ2 to its exclusive fleet

The Boeing 737 BBJ2 is a splendid addition to KlasJet’s exclusive private aircraft fleet as it is set to cater to the specific needs of high-ranking clients travelling in smaller groups.

KlasJet operates 7 corporate and BBJ Boeing 737 from 23 to 68 seats. Also offers ACMI lease services to airlines and tour operators around the world who face challenges with flight schedules, expansion plans, and the supply of backup aircraft. The company’s fleet available for ACMI lease services comprises 6 units of Boeing 737-800 — each with a capacity for 189 passengers.

KlasJet is a family member of Avia Solutions Group, leaders in end-to-end capacity solutions for passenger and cargo airlines worldwide. Its vast portfolio of services to clients includes ACMI, charter and cargo aviation, aircraft leasing and trading, MRO services, business aviation and VIP airline procurement, pilot and crew training, recruitment services, together with multiple complementary services spanning a wide range of associated operations. The Group manages over 100 offices and production facilities globally.

For more information, please visit: www.klasjet.aero and www.aviasg.com

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/ce2e4a06-4419-49c1-ba90-28dbffcb8dc8

https://www.globenewswire.com/NewsRoom/AttachmentNg/5b1ba671-7e18-4a06-accd-41f4e6ca73f6

https://www.globenewswire.com/NewsRoom/AttachmentNg/ea7cb8e9-3448-413a-954b-d25d02a70909

https://www.globenewswire.com/NewsRoom/AttachmentNg/4cef370a-1de1-4531-a17d-46b92282ef95

https://www.globenewswire.com/NewsRoom/AttachmentNg/67654115-fab4-422c-afd3-42548cabab14

https://www.globenewswire.com/NewsRoom/AttachmentNg/1a69f9ae-5ade-4675-9940-6d6e6bec2414

GlobeNewswire Distribution ID 1000768752

Intergalactic Social Media Launches the Galactix Zone Project

The first dynamic NFT game project will leverage dNFT technology to make strides in the worlds of blockchain and gaming.

Featured Image for Intergalactic Social Media, LLC

Featured Image for Intergalactic Social Media, LLC

RICHMOND, Va., Nov. 24, 2022 (GLOBE NEWSWIRE) — Intergalactic Social Media, a collective of crypto advisors and developers spearheaded by founders John Nguyen and Phea Ram, has officially launched its first NFT project, the Galactix Zone. The project, which has now been in development for over two years, is a community-focused effort utilizing a unique Non-Fungible Token (NFT) known as a Dynamic Non-Fungible Token (dNFT). Through its innovative design and model, Intergalactic Social Media aims to break through the mold by redefining NFTs and gaming itself.

After observing several NFT projects, Nguyen and Ram concluded that there was substantial potential for future opportunities and innovations within the space. Over time, they grew increasingly aware of the concerns surrounding the NFT space, including projects that seemed to promote static pixels in an attempt to merely ride a “hype train” and generate quick capital. Other projects went one step further and promised assets to investors just to completely fail to deliver on any of their previous promises.

Galactix Zone, also known as Galactix Zone Kalpa Avian or GKA, will set itself apart through innovations made possible by dNFT technology. Through dNFT, unique properties can be added or removed through the minting process. This innovation is merely scratching the surface of what is to come; GKA is scheduled to be just the first of several projects planning to be released in the ecosystem.

Unlike other projects that promote static NFT images, the Galactix Zone will feature dNFT assets that exist as living, breathing entities with synergistic integration and utility. This unique model gives our project the flexibility to truly innovate in the NFT space.

The implementation of the Galactix Zone project is currently pending internal review, with a detailed release soon to come. The Certik Audit and Certik KYC began on Oct. 31. The Galactix Zone team received a KYC Silver Verified rating on 11/21/2022 and a GEO RISK of a Tier 1 rating – The core team is in a country with the best ratings for international judicial cooperation, criminal justice, anti-money laundering, and corruption. Contextual data suggests the maximum level of geographical accountability, maximizing risk reduction and mitigation. A Certik (Certik.com) audit is an industry-leading security audit for web3 projects. This type of audit assesses smart contracts and blockchain code to address security concerns and identify vulnerabilities. A CertiK Know Your Customer (KYC) verification check is designed to put project teams through a rigorous vetting process while maintaining the highest standards of data protection.

Through these audits and verification checks, the Intergalactic Social Media team hopes to instill a strong sense of trust and transparency within the greater Galactix Zone community.

“Trust and transparency are fundamental principles for our project,” said Nguyen, who serves as the company’s CEO. “These processes will help ensure our community of who we are, what intentions we have currently, and what our future goals for the project will be. Ensuring trust and security is our top priority.”

The Intergalactic Social Media team plans to set aside one percent of its total token supply to be given to charity when the price hits $0.79. The time it will take for the token to reach that price will be determined by the level of pure synergetic teamwork between the developers and the community working together.

“We like to say that ‘FITS’ is in our DNA. FITS stands for fun, innovation, technology, and sustainability,” said Phea, who serves as CTO of Intergalactic Social Media.

“John and I were so captivated by the idea of decentralization when we first began reading about it. It can be so beneficial to all and used as a force for good. With that being said, we gave many of the early projects the benefit of the doubt, only to be burned by bad actors within the industry. We are determined to be different. Giving back to our community is a major focus of ours. We go as far as to say that it is in our tokenomics DNA.”

To learn more about the Galactix Zone, check out the team’s official project announcement video.

About Intergalactic Social Media, LLC

Intergalactic Social Media, LLC is the developer of the Galactix Zone project. Now in development for over two years, the project was initially founded by crypto investors John Nguyen, who serves as the CEO of Intergalactic Social Media, and Phea Ram, who serves as CTO.

In conjunction with a large team of advisors and developers, Nguyen and Ram have worked to bring Galactix Zone, the community-based game focused on giving back to society, to life.

https://discord.gg/2UqSqFJtbA

https://github.com/GalactixZone

https://www.tiktok.com/@galactixzone.io

https://twitter.com/GalactixZone

https://www.youtube.com/@galactixzone

https://www.instagram.com/galactixzone.io

https://www.facebook.com/galactixzone.io

https://www.linkedin.com/company/galactix-zone

Contact Information:
Phea Ram
CTO
marketing@galactixzone.io

Related Files

Galactix Zone Tokenomics 11-23-22.pdf

Related Images

Image 1

This content was issued through the press release distribution service at Newswire.com.

Attachment

GlobeNewswire Distribution ID 8702894

Junshi Biosciences Announces Submission of a Marketing Authorization Application for Toripalimab to the UK Medicines and Healthcare Products Regulatory Agency

— 2nd MAA submission in Europe reflects toripalimab’s steady yet speedy progress towards global commercialization

SHANGHAI, China, Nov. 24, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the company has submitted a marketing authorization application (“MAA”) to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (“MHRA”) for toripalimab. The indications requested in the MAA are: 1) Toripalimab, in combination with cisplatin and gemcitabine, for the first-line treatment of patients with locally recurrent or metastatic nasopharyngeal carcinoma (“NPC”) and 2)Toripalimab, in combination with paclitaxel and cisplatin, for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma (“ESCC”). Junshi Biosciences also submitted a MAA to the European Medicines Agency (“EMA”) for toripalimab for the same indications in mid-November.

“Within a single month, we were able to submit marketing authorization applications for toripalimab to two major European regulatory agencies,” said Dr. Patricia Keegan, Chief Medical Officer of Junshi/TopAlliance Biosciences. “This is emblematic of our determination and corporate efficiency in bringing innovative drugs to patients worldwide. In the coming days, we will work closely with the MHRA to promote the clinical development and application of emerging therapies in the UK.”

The MAA submission for NPC and ESCC is based on the results from JUPITER-02 (an international randomized, placebo-controlled, double-blinded Phase III trial, NCT03581786) and JUPITER-06 (a randomized, placebo-controlled, double-blinded, multi-center Phase III trial, NCT03829969).

The JUPITER-02 results were first presented in the plenary session of the American Society of Clinical Oncology (“ASCO”) 2021 annual meeting (#LBA2) and subsequently published in detail as the cover article of the September 2021 issue of Nature Medicine. According to its final progression-free survival (PFS) analysis, the toripalimab plus chemotherapy arm had a significantly longer PFS than the placebo plus chemotherapy arm as assessed by a blinded independent radiology committee (BIRC) with median PFS of 21.4 vs. 8.2 months, hazard ratio (HR)=0.52 (95% CI: 0.37-0.73), two-sided p<0.0001.

In 2021, two indications for the treatment of NPC were approved by the China National Medical Products Administration (“NMPA”), thereby making toripalimab the world’s first immune checkpoint inhibitor approved for the treatment of NPC. In the the United States, the NPC indications of toripalimab have been granted 2 Breathrough Therapy Designations and 1 Orphan Drug Designation by the Food and Drug Administration (“FDA”), while the Biologics License Application (“BLA”) for toripalimab for the treatment of NPC is under review. If approved, toripalimab will be the first and only drug approved for the treatment of NPC in the U.S. In Europe, toripalimab was designated as an orphan medicinal product by the European Commission (“EC”) for the treatment of NPC.

The JUPITER-06 results were first presented in a mini-oral session during the 2021 European Society for Medical Oncology (“ESMO”) Congress and later published in Cancer Cell with an editorial preview. The overall survival (OS) and PFS were significantly better in the toripalimab plus chemotherapy arm than in the placebo plus chemotherapy arm, with a median OS of 17 vs. 11 months (HR=0.58, 95% CI: 0.43-0.78, P=0.0004) and PFS HR=0.58 (95% CI: 0.46-0.74), p<0.0001.

In May 2022, the supplemental new drug application (“sNDA”) for toripalimab in combination with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic ESCC was approved by the NMPA in China. Additionally, US FDA has also granted an orphan drug designation to toripalimab for the treatment of patients with ESCC.

About Nasopharyngeal Carcinoma
NPC is a malignant tumor that occurs in the nasopharyngeal mucosal epithelium and is one of the most common head and neck cancers in China. According to the World Health Organization, the number of newly diagnosed NPC cases in 2020 has exceeded 130,000 worldwide. Due to the location of the primary tumor, surgery is rarely an option, and patients with localized disease are treated primarily with chemotherapy and radiotherapy. In the United States and Europe, there are presently no drugs approved for the treatment of NPC, for which recommendations for initial treatment (gemcitabine and cisplatin) are based on randomized trials conducted in China.

About Esophageal Cancer
Esophageal cancer is one of the most common malignant tumors in alimentary tract. According to data released by GLOBOCAN 2020, 604,100 new esophageal cancer cases and 544,076 deaths due to esophageal cancer occurred globally. The incidence and death rates of esophageal cancer ranked seventh and sixth among all malignant tumors around the world. ESCC and esophageal adenocarcinoma are the two main histological subtypes of esophageal cancer. For patients with advanced ESCC, recently updated ESMO guidelines recommend a platinum-fluoropyrimidine doublet with a PD-1 blocking antibody for treatment of locally advanced or metastatic ESCC. Of note, the indications for those PD-1 inhibitors approved in Europe are restricted to a subset of patients with ESCC. Therefore, there is an urgent unmet need for new drugs and treatments to extend the survival of patients with ESCC, particularly those with low PD-1 tumor expression.

About Toripalimab
Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system’s ability to attack and kill tumor cells.

More than thirty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and European countries. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.

In China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI®). Currently, there are six approved indications for toripalimab in China:

  1. unresectable or metastatic melanoma after failure of standard systemic therapy;
  2. recurrent or metastatic NPC after failure of at least two lines of prior systemic therapy;
  3. locally advanced or metastatic urothelial carcinoma that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy;
  4. in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic NPC;
  5. in combination with paclitaxel and cisplatin in first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic ESCC;
  6. in combination with pemetrexed and platinum as the first-line treatment in EGFR mutation-negative and ALK mutation-negative, unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer (“NSCLC”).

The first three indications have been included in the National Reimbursement Drug List (“NRDL”) (2021 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for treatment of melanoma and NPC.

In the United States, the FDA is reviewing the BLA resubmission for toripalimab in combination with gemcitabine and cisplatin as first-line treatment for patients with advanced recurrent or metastatic NPC and for toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy. The FDA has set a PDUFA action date for December 23, 2022. The FDA has granted Breakthrough Therapy designations for toripalimab in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and Orphan Drug designations for the treatment of esophageal cancer, NPC, mucosal melanoma, soft tissue sarcoma, and small cell lung cancer (“SCLC”).

In Europe, toripalimab was also designated as an orphan medicinal product by the EU’s European Commission for the treatment of NPC. In November 2022, MAA was submitted to the EMA and MHRA for: 1) toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC and 2) toripalimab combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic ESCC.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.

In the face of the pandemic, Junshi Biosciences’ response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. Among the many drug candidates is JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2 and the result of the combined efforts of Junshi Biosciences, the Institute of Microbiology of the Chinese Academy of Science and Lilly. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. Meanwhile, VV116, a new oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, is in global Phase III clinical trials. The JS016 and VV116 programs are a part of the company’s continuous innovation for disease control and prevention of the global pandemic.

Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http://junshipharma.com.

Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-6105 8800

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

GlobeNewswire Distribution ID 8703015

Eco-warrior Paul Watson, Scourge of Whalers, Returns to the Seas

Canadian-American eco-warrior Paul Watson, ousted from the Sea Shepherd conservationist organization he founded, says he is back in business with a new ship and crew and is ready to resume tormenting the world’s whalers and others he sees as despoilers of the world’s oceans.
“After being knocked down, we have fully recovered and we’re ready to return to battle on the high seas,” Watson declared in a digital announcement earlier this month. “The new Captain Paul Watson Foundation is here and it’s ready to aggressively take on all enemies that look to do harm to our ocean and our planet.”
Watson is among the most controversial figures in the environmental movement, in and out of legal trouble on several continents over aggressive tactics, which have included ramming and sinking or fouling the propellers of whaling vessels. Some of his exploits have been portrayed in the reality TV series Whale Wars, shown on Animal Planet.
His advocacy of “direct action” led to him being ousted in 1977 from the board of Greenpeace, where he was an early member, and his founding of the Sea Shepherd Conservation Society where he gained notoriety as a scourge of Norwegian, Japanese and Icelandic whalers, who operate despite global ban on whaling under an exception allowing for research.
Among his most dramatic actions was the sinking of two whaling vessels in a harbor in Iceland by his society members – an action for which Watson claimed personal responsibility. Over his career, such tactics led to legal action in Canada, the United States, Costa Rica, Norway and Japan, although he has never been convicted of a major crime.
Nevertheless, it all became too much for his fellow board members at Sea Shepherd, who removed him from the board and limited his activities, leading him to cut all ties with the group in July.
“I was marginalized and told to be a paid and quiet figurehead as they changed the direction of the organization away from confrontational and controversial campaigns,” Watson told VOA in a telephone interview and follow-up emails.
“I said I could not participate or support this change. Sea Shepherd should not be Oceana or Greenpeace. Our approach should always be aggressive, direct action.”
To that end, he has established the Captain Paul Watson Foundation and, he said, “We’re going to rebuild our navy. I call it Neptune’s Navy.”
Watson said he recently completed the purchase in Britain of a new ship, to be named the John Paul DeJoria, and, so far, has taken on seven crew members, mostly engineers. “I am also looking for two additional ships” he said, and he has “a few dozen” applicants to sail with him, mainly former Sea Shepherd officers and crew.
Asked whether he expects to resume his pursuit of whaling ships, which according to the NGO Whale and Dolphin Conservation, have killed nearly 40,000 large whales since commercial whaling was banned in 1986, he replied, “Always. It has been my lifetime ambition to eradicate whaling.”
Nor does he plan to tone down the tactics that have outraged his critics in the past.
“Why would I consider doing that? I established the approach of aggressive non-violence and that continues to be my primary strategy because it is effective. I have not changed my approach for over half a century,” he told VOA.
As for ramming whaling ships, “That depends on the situation, i.e. legal status, location and logistics. I have not rammed a ship since 2013 but it’s always a possibility.”
But, he maintained, “We’re not going to injure anyone. I’ve never injured anyone in my entire career.”
That fact has done little to assuage Watson’s critics, including the Japanese government, which once labeled the Sea Shepherd society an “eco-terrorist” organization.
“A U.S. court declared Sea Shepherds to be ‘pirates’ after considering their history of ramming ships, hurling containers of acid, and other aggression,” noted Rick Berman, executive director of the U.S.-based Center for Organizational Research and Education, which casts a skeptical eye on some environmental and animal rights groups.
“When you hear Paul Watson claim he has a good cause, just remember ISIS says the same thing,” Berman told VOA in an email exchange.
On the other side of the ledger, Watson has been presented in Paris with a Jules Verne Award for his role as a protector of the environment and was named by Time magazine among the Top 20 environmental heroes of the 20th century.
The activist credits public support for his cause for his ability to avoid having ever been convicted of a felony in any country.
Years after his organization scuttled the two Icelandic whaling vessels in 1986, he flew to Iceland and asked to be booked for the crime. “They put me on a plane,” he said. “Iceland knew to put me on trial would be to put themselves on trial for their illegal activities.”
But, he said, he understands why many other conservationists want to keep him at arm’s length.
“We fill a specific niche within the marine conservation movement,” he emailed. “We are not for everyone. … Although many quietly agree and support what we do, they are hesitant to be seen with us in the light of day.”

Source: Voice of America

Wildlife Summit to Vote on Shark Protections

Delegates at a global summit on trade in endangered species were scheduled to decide Thursday whether to approve a proposal to protect sharks, a move that could drastically reduce the lucrative and often cruel shark fin trade.
The proposal would place dozens of species of the requiem shark and the hammerhead shark families on Appendix II of the Convention on International Trade in Endangered Species (CITES).
The appendix lists species that may not yet be threatened with extinction but may become so unless trade in them is closely controlled.
If Thursday’s plenary meeting gives the green light, “it would be a historic decision,” Panamanian delegate Shirley Binder told AFP.
“For the first time, CITES would be handling a very large number of shark species, which would be approximately 90% of the market,” she said.
Spurring the trade is the insatiable Asian appetite for shark fins, which make their way onto dinner tables in Hong Kong, Taiwan and Japan.
Despite being described as gelatinous and almost tasteless, shark fin soup is viewed as a delicacy and is enjoyed by the very wealthy, often at weddings and expensive banquets.
Shark fins, representing a market of about $500 million per year, can sell for about $1,000 a kilogram.
From villain to conservation darling
Sharks have long been seen as the villain of the seas they have occupied for more than 400 million years, terrifying people with their depiction in films such as “Jaws” and their occasional attacks on humans.
However, these ancient predators have undergone an image makeover in recent years as conservationists have highlighted the crucial role they play in regulating the ocean ecosystem.
According to the Pew Environment Group, between 63 million and 273 million sharks are killed every year, mainly for their fins and other parts.
With many shark species taking more than 10 years to reach sexual maturity, and having a low fertility rate, the constant hunting of the species has decimated their numbers.
In many parts of the world, fisherman lop the sharks’ fins off at sea, tossing the shark back into the ocean for a cruel death by suffocation or blood loss.
The efforts by conservationists led to a turning point in 2013, when CITES imposed the first trade restrictions on some shark species.
“We are in the middle of a very large shark extinction crisis,” Luke Warwick, director of shark protection for the nongovernmental organization Wildlife Conservation Society, told AFP at the beginning of the summit.
Heated debate
Thursday’s vote followed a fierce debate that lasted nearly three hours, with Japan and Peru seeking to reduce the number of shark species that would be protected.
Japan had proposed that the trade restriction be reduced to 19 species of requiem sharks, and Peru called for the blue shark to be removed from the list.
Both suggestions were rejected, however.
“We hope that nothing extraordinary happens and that these entire families of sharks are ratified for inclusion in Annex II,” Chilean delegate Ricardo Saez told AFP.
Several delegations, including host Panama, displayed stuffed toy sharks on their tables during the earlier Committee I debate.
The plenary was also scheduled to vote on ratifying a proposal to protect guitarfish, a species of ray.
The shark initiative was one of the most discussed at this year’s CITES summit in Panama, with the proposal co-sponsored by the European Union and 15 countries.
Participants at the summit considered 52 proposals to change species protection levels.
CITES, which came into force in 1975, has set international trade rules for more than 36,000 wild species. Its signatories include 183 countries and the European Union.

Source: Voice of America